Disease · MONDO_0041052
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| G-ER vs Placebo: serious adverse events | 4 of 221 | 6 of 231 | 452 | NCT00636636 | Trial comparisons |
| G-ER vs Placebo: Patient Global Impression of Change (PGIC) | 94 of 220 | 77 of 230 | 450 | NCT00636636 | Trial comparisons |
| G-ER vs Placebo: Clinical Global Impression of Change (CGIC) | 97 of 220 | 78 of 230 | 450 | NCT00636636 | Trial comparisons |
| Pregabalin CR DB vs Placebo DB: Participants With Secondary LTR Based on 5 Day Rolling Average Diary Results | 49 of 208 | 87 of 205 | 413 | NCT01270828 | Trial comparisons |
| Pregabalin CR DB vs Placebo DB: Number of Participants With Loss of Therapeutic Response. | 29 of 208 | 63 of 205 | 413 | NCT01270828 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 2 of 111 | 0 of 109 | 220 | NCT01455428 | Trial comparisons |
| XPF-002 vs Placebo: serious adverse events | 1 of 62 | 1 of 63 | 125 | NCT01195636 | Trial comparisons |
| GEn 1200 mg vs GEn 3600 mg: Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) at the Last Week of Each Treatment Period Using LOCF Data | 17 of 63 | 28 of 61 | 124 | NCT00617461 | Trial comparisons |
| XPF-002 vs Placebo: Proportion of Subjects Using Rescue Analgesic Medications During XPF-002 Treatment Compared to Placebo Treatment | 38 of 57 | 40 of 57 | 114 | NCT01195636 | Trial comparisons |
| XPF-002 vs Placebo: Proportion of Subjects Achieving 50% Improvement in Mean Daily Pain Score From Baseline to Week 3 on XPF-002 Treatment Compared to Placebo Treatment | 15 of 52 | 6 of 52 | 104 | NCT01195636 | Trial comparisons |
XPF-002 vs Placebo: Proportion of Subjects Achieving at Least a 1 Point Improvement in Mean Daily Pain Score (Measured Using the 11-point Likert NRS) From Baseline to Week 3 on XPF-002 Compared to Placebo | 22 of 52 | 19 of 52 | 104 | NCT01195636 | Trial comparisons |
| XPF-002 vs Placebo: Proportion of Subjects Achieving 30% Improvement in Mean Daily Pain Score From Baseline to Week 3 on XPF-002 Treatment Compared to Placebo Treatment | 21 of 52 | 12 of 52 | 104 | NCT01195636 | Trial comparisons |
| GEn 1200 mg vs GEn 3600 mg: Number of Participants Who Are Responders on the Clinical Global Impression of Change (CGIC) Questionnaire at the Last Week of Each Treatment Period Using LOCF Data | 15 of 53 | 18 of 48 | 101 | NCT00617461 | Trial comparisons |
| Tapentadol vs Placebo: serious adverse events | 4 of 60 | 3 of 31 | 91 | NCT01124617 | Trial comparisons |
| LX9211 vs Placebo: Number of Participants Discontinuing Treatment Due to Lack of Efficacy Defined as Increase in ADPS From Baseline of ≥30% Based on Question 5 of the ZBPI | 0 of 38 | 1 of 41 | 79 | NCT04662281 | Trial comparisons |
| Moderate Renal Impairment vs Severe Renal Impairment: deaths from any cause | 0 of 30 | 0 of 5 | 35 | NCT02607280 | Trial comparisons |
| Moderate Renal Impairment vs Severe Renal Impairment: serious adverse events | 1 of 30 | 0 of 5 | 35 | NCT02607280 | Trial comparisons |
| Double Blind Treatment Period Civamide Nasal Spray vs Double Blind Treatment Period Placebo Nasal Spray: serious adverse events | 0 of 6 | 1 of 5 | 11 | NCT01886313 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0041052/comparisons